



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/588810/2013

European Medicines Agency decision

P/0269/2013

of 30 October 2013

on the acceptance of a modification of an agreed paediatric investigation plan for lurasidone (hydrochloride) (EMA-001230-PIP01-11-M01) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.



European Medicines Agency decision

P/0269/2013

of 30 October 2013

on the acceptance of a modification of an agreed paediatric investigation plan for lurasidone (hydrochloride) (EMA-001230-PIP01-11-M01) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the European Medicines Agency's decision P/0145/2012 issued on 23 July 2012,

Having regard to the application submitted by Takeda Pharma A/S on 24 June 2013 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 13 September 2013, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation.
- (2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan.

¹ OJ L 378, 27.12.2006, p.1.

² OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for lurasidone (hydrochloride), film-coated tablet, oral use, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to Takeda Pharma A/S, Langebjerg 1, DK-4000 – Roskilde, Denmark.

Done at London, 30 October 2013

For the European Medicines Agency
Guido Rasi
Executive Director
(Signature on file)

EMA/PDCO/390785/2013

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan

EMA-001230-PIP01-11-M01

Scope of the application

Active substance(s):

Lurasidone (hydrochloride)

Condition(s):

Treatment of schizophrenia

Pharmaceutical form(s):

Film-coated tablet

Route(s) of administration:

Oral use

Name / corporate name of the PIP applicant:

Takeda Pharma A/S

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Takeda Pharma A/S submitted to the European Medicines Agency on 24 June 2013 an application for modification of the agreed paediatric investigation plan with a deferral and a waiver as set out in the European Medicines Agency's decision P/0145/2012 issued on 23 July 2012.

The application for modification proposed changes to the agreed paediatric investigation plan.

The procedure started on 17 July 2013.

Scope of the modification

Some measures and timelines of the agreed paediatric investigation plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:
 - to agree to changes to the paediatric investigation plan in the scope set out in the Annex I of this opinion.

The Icelandic and the Norwegian Paediatric Committee members agree with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

London, 13 September 2013

On behalf of the Paediatric Committee
Dr Dirk Mentzer, Chairman
(Signature on file)

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed Paediatric Investigation Plan

1. Waiver

1.1. Condition: Treatment of schizophrenia

The waiver applies to:

- All subsets of the paediatric population from birth to less than 13 years of age;
- for film-coated tablet for oral use;
- on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subset(s).

2. Paediatric Investigation Plan

2.1. Condition: Treatment of schizophrenia

2.1.1. Indication(s) targeted by the PIP

Treatment of schizophrenia

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 13 to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Film-coated tablet

2.1.4. Studies

Area	Number of studies	Description
Quality	0	Not applicable.
Non-clinical	0	Not applicable.
Clinical	4	Study 1: Open-label, multicentre, single and multiple fixed ascending dose study to evaluate pharmacokinetics, safety, and tolerability of lurasidone in the paediatric population (D1050300) Study 2: Randomised, parallel, double-blind, placebo-controlled, fixed-dose regimen, multicentre, study to evaluate the efficacy and safety of lurasidone in adolescent patients with schizophrenia (D1050301)

		Study 3: A 104-week, flexible-dose, open-label multicentre extension study to evaluate the long-term safety and effectiveness of lurasidone in adolescent patients with schizophrenia (D1050302) Study 4: Randomised, double-blind, active-controlled, non-inferiority, flexible dose study to evaluate the maintenance of the efficacy of lurasidone compared to aripiprazole in the treatment of adolescent patients with schizophrenia (5474)
--	--	--

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety or efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By April 2018
Deferral for one or more studies contained in the paediatric investigation plan:	Yes